Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 6, 2005, Pages 301-306

  Bank, Micha I ^a,c   Gudbrand, Charlotte ^a   Rengtved, Pia ^a   Carstensen, Henrik ^a   Fadeel, Bengt ^b   Henter, Jan Inge ^b   Petersen, Bodil Laub ^a,c  

^a Mental Health Services CPH   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Rigshospitalet   (Denmark)

Author keywords

Apoptosis; FADD MORT1 FLICE caspase 8; Fas APO 1 CD95; FLIP FLICE inhibitory protein; Langerhans cell histiocytosis

Indexed keywords

CASPASE 8; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PARAFFIN;

ADOLESCENT; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HISTIOCYTOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LANGERHANS CELL; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE SLICE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASES; CHILD; ENZYME ACTIVATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; TONSIL;

EID: 21244490862     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000168725.57143.52     Document Type: Article

References (53)

1. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999;35:747-769.
2. Laman JD, Leenen PJM, Annels NE, et al. Langerhans-cell histiocytosis "insight into DC biology." Trends Immunol. 2003;24:190-196.
3. Fadeel B, Renter J-I. Langerhans-cell histiocytosis: neoplasia or unbridled inflammation? Trends Immunol. 2003;24:409-411.
4. Willman CL, Busque L, Griffith BB, et al. Langerhans cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med. 1994;331: 154-160.
5. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343:767-768.
6. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer. 1994;70 (Suppl XXIII):37-40.
7. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999;94:4195-4201.
8. Egeler RM, Favara BE, Laman JD, et al. Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer. 2000;36:2105-2110.
9. Fleming MD, Pinkus JL, Alexander SW, et al. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003;101:2473-2475.
10. Annels NE, da Costa CET, Prins FA, et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med. 2003;197: 1385-1390.
11. Geissmann F, Emile JF, Andry P, et al. Lack of expression of E-cadherin is associated with dissemination of Langerhans cell histiocytosis and poor outcome. J Pathol. 1997;181:301-304.
12. Robertson JD, Fadeel B, Zhivotovsky B, et al. Centennial Nobel Conference on apoptosis and human disease. Cell Death Diff. 2002;9: 468-475.
13. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and rumour counterattack. Immunol Cell Biol. 2002;80:131-137.
14. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407:789-795.
15. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol. 2001;1:50-58.
16. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29-55.
17. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
18. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935-946.
19. Petersen BL, Rengtved P, Bank MI, et al. High expression of markers of apoptosis in Langerhans cell histiocytosis. Histopathology. 2003;42:186-193.
20. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood. 1999;94:1727-1737.
21. Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114:63-69.
22. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. Med Pediatr Oncol. 1997;29:157-166.
23. Lahey E. Histiocytosis X: an analysis of prognostic factors. J Pediatr. 1975;87:184.
24. Ashany D, Savir A, Bhardwaj N, et al. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J Immunol. 1999;63: 5303-5311.
25. L and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000;95:3478-3482.
26. L. Cancer Immunol Immunother. 2002;51:139-144.
27. Savell VH Jr, Sherman T, Scheuermarm RH, et al. Bcl-2 expression in Langerhans cell histiocytosis. Pediatr Dev Pathol. 1998;1:210-215.
28. Scheuten B, Egeler RM, Leenen PJ, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002;24:727-732.
29. Bratton SB, Lewis J, Butterworth M, et al. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95-and Bax-induced apoptosis. Cell Death Differ. 2002;9:881-892.
30. Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993;178: 2231-2235.
31. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med. 1998;187:123-128.
32. Zhang J, Cado D, Chen A, et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296-299.
33. Newton K, Harris AW, Bath ML, et al. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998;17:706-718.
34. Strasser A, Newton K. FADD/MORT1, a signal transducer that can promote cell death or cell growth. Int J Biochem Cell Biol. 1999;31:533-537.
35. Rescigno M, Piguet V, Valzasina B, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon α in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med. 2000;192:1661-1668.
36. Weintraub M, Bhatia KG, Chandra RS, et al. p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 1998;20:12-17.
37. Bank MI, Rengtved P, Carstensen H, et al. p53 expression in biopsies from children with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002;24:733-736.
38. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;15:3032-3040.
39. Müller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998; 188:2033-2045.
40. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
41. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
42. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol. 2000;78:334-341.
43. Agostini C, Perin A, Semenzato G. Cell apoptosis and granulomatous lung diseases. Curr Opin Pulm Med. 1998;4:261-266.
44. Bank MI, Rengtved P, Carstensen H, et al. An evaluation of histopathological parameters, demonstration of proliferation by Ki-67 and mitotic bodies. APMIS. 2003;111:300-308.
45. Hage C, Willman CL, Favara BE, et al. Langerhans cell histiocytosis (histiocytosis X): immunotype and growth fraction. Hum Pathol. 1993;24: 840-845.
46. Brabencova E, Tazi A, Lorenzato M, et al. Langerhans cells in Langerhans cell granulomatosis are not actively proliferating cells. Am J Pathol. 1998; 152:1143-1149.
47. Perlman H, Pagilari LJ, Volin MV. Regulation of apoptosis and cell cycle activity in rheumatoid arthritis. Curr Mol Med. 2001;1:597-608.
48. Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann NY Acad Sci. 2002;973;166-180.
49. Noffsinger A, Unger B, Fenoglio-Preiser CM. Increased cell proliferation characterizes Crohn's disease. Mod Pathol. 1998;11:1198-1203.
50. Glotzbecker MP, Carpentierie DF, Dormans JP. Langerhans cell histiocytosis: a primary viral infection of bone? J Pediatr Orthop. 2004; 24:123-129.
51. Samady L, Costigliola E, MacCormac L, et al. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs(-) HSV vectors for dendritic cell-mediated immunotherapy. J Virol. 2003;77:3768-3776.
52. Muller DB, Raftery MJ, Kather A, et al. Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus. Eur J Immunol. 2004;34:941-951.
53. Renter J-I, Karlen J, Calming U, et al. Successful treatment of Langerhans' cell histiocytosis with etanercept. N Engl J Med. 2001; 345:1577-1578.